


UPDATE ON HIGH TECH MEDICINES FOR ATOPIC DERMATITIS



The HSE introduced a managed access protocol (MAP) for High Tech Medicines for Atopic Dermatitis in April 2021. The aim of the MAP is to provide patients with moderate-to-severe atopic dermatitis and previous treatment failure with immunosuppressant medication, with access to novel treatments for atopic dermatitis. Different types of medication are covered under this MAP, sub-cutaneous biological agents (dupilumab, tralokinumab) and oral treatments (upadacitinib and abrocitinib), that reduce the activity of the immune system.

To date, the HSE have approved 69 prescribers for High Tech Medicines for Atopic Dermatitis under this protocol. By June 2023, over 500 patients were accessing treatment with these high tech medicines for atopic dermatitis each month under the High Tech Arrangement.

The application system for drugs for atopic dermatitis successfully migrated from a paper-based system to an online application system in April 2023.

An in-depth overview of the first year of the managed access protocol for high tech medicines for atopic dermatitis was published in the [Irish Journal of Medical Science](#).

August 2023

HSE Medicines Management Programme.